Back

Susceptibility of glycopeptide-resistant Enterococcus faecium to tigecycline, dapto-mycin, linezolid, and quinupristin-dalfopristin

Abstract number: 1734_21

Abb J.

Objective: To study the in vitro activity of the glycylcycline tigecycline, the lipopeptide daptomy-cin, the oxazolidinone linezolid and the streptogramin quinupristin-dalfopristin against glycopeptide-resistant Enterococcus faecium (GRE).

Methods: Sixty primary GRE isolates from hospitalised patients were collected between January and December 2004. Minimum inhibitory concentrations of vancomycin, tei-coplanin, tigecycline, daptomycin, linezolid and quinupristin-dalfopristin against E. faecium strains were determined by the E test. E. faecalis ATCC 29212 was used as a control strain.

Results: MIC 50, MIC 90, and MIC range values are demonstrated in the table. According to CLSI standard MS 100–S15 criteria all GRE isolates were fully susceptible to tigecy-cline, daptomycin, and quinupristin-dalfopristin. GRE strains, however, demonstrated a high rate of only intermediate sensitivity (82 percent) against linezolid (MIC: 3.0 to 4.0 mg/L), but none of the isolates was fully resistant to the oxazolidinone.

Antimicrobial agentsMIC (mg/L)
MIC50MIC90Range  
Tigecycline0.0470.0940.032–0.125
Daptomycin1.51.50.5–3.0
Linezolid3.04.00.75–4.0
Quinupristin–Dalfopristin1.01.50.38–2.0
Teicoplanin4812816–>256
Vancomycin>256>256128–>256

Conclusion: The present and previous in vitro studies show that tigecycline, daptomycin, quin-upristin-dalfopristin, and linezolid may be useful alternative agents for the treatment of patients with GRE infections. The rapid emergence of E. faecium isolates with re-sistance to the novel compounds, however, underlines the need for careful pre-therapy susceptibility testing.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top